Ratings IMCD N.V.

Equities

IMCD

NL0010801007

Real-time Euronext Amsterdam Other stock markets 08:29:17 03/05/2024 pm IST			5-day change	1st Jan Change
140.8 ^EUR	+0.18%		-8.81%	-10.66%

26/04	Transcript : IMCD N.V., Q1 2024 Earnings Call, Apr 26, 2024
24/04	IMCD's Spanish Unit to Buy Cobapharma	MT

Summary

The company presents an interesting fundamental situation from a short-term investment perspective.
The company has a good ESG score relative to its sector, according to Refinitiv.

Strengths

For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
Over the past four months, analysts' average price target has been revised upwards significantly.
There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
Historically, the company has been releasing figures that are above expectations.

Weaknesses

The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
The company benefits from high valuations in earnings multiples.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
The valuation of the company is particularly high given the cash flows generated by its activity.
The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
Over the past twelve months, analysts' opinions have been revised negatively.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Specialty Chemicals

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
IMCD N.V.	-10.66%	8.56B		A-
REDOX LIMITED	+34.47%	1.09B		-
TOPCO TECHNOLOGIES CORP.	+10.50%	179M	-	-
GHW INTERNATIONAL	+9.76%	113M	-	-
HP ADHESIVES LIMITED	+3.54%	113M	-	-
SHANKAR LAL RAMPAL DYE-CHEM LIMITED	+8.18%	88.22M	-	-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes